896731-82-1
896731-82-1 structure
- Name: Conatumumab
- Chemical Name: 4-Chloro-2-[(2-furylmethyl)amino]-5-sulfamoylbenzoic acid-1,3-dipropyl-8-(tricyclo[3.3.1.03,7]non-3-yl)-3,7-dihydro-1H-purine-2,6-dione (1:1)
- CAS Number: 896731-82-1
- Molecular Formula: C32H39ClN6O7S
- Molecular Weight: 687.206
- Catalog: Research Areas Cancer
- Create Date: 2018-07-03 03:43:05
- Modify Date: 2025-08-25 18:52:11
-
Conatumumab (AMG 655) is a human monoclonal agonist antibody against human death receptor 5 (DR5, TRAILR2) (Kd: 1 nM for the long form of DR5, 0.8 nM for the short form of DR5). Conatumumab induces apoptosis via caspase activation. Conatumumab can be used in the research of cancers. [1][2][3].
| Name | 4-Chloro-2-[(2-furylmethyl)amino]-5-sulfamoylbenzoic acid-1,3-dipropyl-8-(tricyclo[3.3.1.03,7]non-3-yl)-3,7-dihydro-1H-purine-2,6-dione (1:1) |
|---|---|
| Synonyms |
4-Chloro-2-[(2-furylmethyl)amino]-5-sulfamoylbenzoic acid - 1,3-dipropyl-8-(tricyclo[3.3.1.03,7]non-3-yl)-3,7-dihydro-1H-purine-2,6-dione (1:1)
Benzoic acid, 5-(aminosulfonyl)-4-chloro-2-[(2-furanylmethyl)amino]-, compd. with 8-(hexahydro-2,5-methanopentalen-3a(1H)-yl)-3,7-dihydro-1,3-dipropyl-1H-purine-2,6-dione (1:1) |
| Description | Conatumumab (AMG 655) is a human monoclonal agonist antibody against human death receptor 5 (DR5, TRAILR2) (Kd: 1 nM for the long form of DR5, 0.8 nM for the short form of DR5). Conatumumab induces apoptosis via caspase activation. Conatumumab can be used in the research of cancers. [1][2][3]. |
|---|---|
| Related Catalog | |
| Target |
IC50: DR5 (<1 nM)[2] |
| In Vitro | Conatumumab (0-10 μg/mL，4 小时) 激活 Colo205、H-2122 和 MiaPaCa2 细胞中的 caspase-3/7[2]。 Conatumumab (0-10 μg/mL，24 小时) 降低敏感肿瘤细胞系 (Colo205、H-2122 和 MiaPaCa2 细胞) 的细胞活力[2]。 Cell Viability Assay[2] Cell Line: Colo205, H-2122, and MiaPaCa2 cells Concentration: 0-10 μg/mL Incubation Time: 24 h Result: Dose-dependently inhibited cell viability. |
| In Vivo | Conatumumab (0-100 μg，腹腔注射，每周两次) 抑制 Colo205、H2122 或 MiaPaCa2/T2 异种移植肿瘤的小鼠的肿瘤生长[2]。 Conatumumab (2.5 μg，i.p.，每周 3 次) 增强化疗药物 (CPT11，HY- 16562) (80 mg/kg) 在 Colo 205 移植瘤中的抗肿瘤活性[2]。 Animal Model: Mice bearing Colo205, H2122, or MiaPaCa2/T2 xenograft tumors[2] Dosage: 0, 0.1, 0.3, 1, 3, 10, 30, 100 μg Administration: Intraperitoneal injection (i.p.), twice weekly. Result: Dose-dependently inhibited tumor growth. Induced caspase-3 activation in tumors (determined by IHC). |
| References |
| Molecular Formula | C32H39ClN6O7S |
|---|---|
| Molecular Weight | 687.206 |
| Exact Mass | 686.228943 |